You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
一品紅(300723.SZ):子公司帕瑞昔布鈉原料藥通過CDE技術審評
格隆匯 03-03 11:52

格隆匯3月3日丨一品紅(300723.SZ)公佈,近日,公司全資子公司廣州一品紅製藥有限公司(簡稱“一品紅製藥”)帕瑞昔布鈉原料藥通過國家藥品監督管理局藥品審評中心(簡稱“CDE”)技術審評,在CDE原料藥、藥用輔料和藥包材登記信息公示平台上顯示登記號轉為“A”狀態。

帕瑞昔布鈉是由美國法瑪西亞公司研發的第一個可靜脈注射或肌肉注射用的選擇性COX-2抑制劑,通過特異性抑制COX-2阻斷花生四烯酸合成前列腺素而發揮抗炎鎮痛作用,並可減少麻醉性鎮痛藥的用量。

目前在CDE原料藥、藥用輔料和藥包材登記信息公示平台上登記帕瑞昔布鈉原料藥的企業共有40家,其中與製劑共同審評審批結果為“A”的企業有31家。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account